|Bid||1.35 x 1500|
|Ask||3.00 x 1000|
|Day's Range||1.72 - 2.15|
|52 Week Range||0.38 - 4.50|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 18, 2017 - Oct 23, 2017|
|Forward Dividend & Yield||0.00 (0.00%)|
|1y Target Est||3.00|
NeuroMetrix Inc (NASDAQ:NURO), a USD$3.90M small-cap, is a healthcare company operating in an industry, which faces key trends such as rising demand fuelled by an aging population and the growingRead More...
NeuroMetrix Inc (NASDAQ:NURO), a healthcare equipment and supplies company based in United States, saw significant share price volatility over the past couple of months on the NasdaqCM, rising to theRead More...
NeuroMetrix, Inc. today closed a $3.5 million private placement of 3,500 shares of Series F convertible preferred stock at a price of $1,000 per share that are convertible into 1,330,798 shares of common stock at a conversion price of $2.63 per share.
NEW YORK, NY / ACCESSWIRE / October 19, 2017 / NeuroMetrix, Inc. (NASDAQ: NURO ) will be discussing their earnings results in their Q3 Earnings Call to be held October 19, 2017 at 8:00 AM Eastern Time. ...
NeuroMetrix, Inc. announced today that it plans to issue its 2017 third quarter financial results before the opening of the market on Thursday October 19, 2017. The Company will host a conference call at 8:00 a.m., Eastern Time on October 19, 2017 to discuss its financial results as well as business developments affecting the Company.
If you are a shareholder in NeuroMetrix Inc’s (NASDAQ:NURO), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of your portfolioRead More...
NeuroMetrix, Inc. today announced it will be a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC.
NeuroMetrix, Inc. today reported that it will present two scientific posters at the upcoming PAINWeek national conference to be held in Las Vegas, NV, September 5-9.
In recognition of Pain Awareness Month this September, NeuroMetrix, Inc. is partnering with the U.S. Pain Foundation, a nonprofit organization dedicated to serving those who live with pain conditions and their providers, to raise awareness of the issues impacting the chronic pain community.
Research Desk Line-up: DENTSPLY SIRONA Post Earnings Coverage LONDON, UK / ACCESSWIRE / August 17, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for ...
NeuroMetrix, Inc. announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,731,126. The patent covers novel technology whereby the Quell® device automatically modulates therapeutic neurostimulation based on the user’s sleep characteristics.
NeuroMetrix, Inc. today reported an agreement with Fukuda Denshi for DPNCheck® distribution in Japan. DPNCheck is NeuroMetrix’ rapid, accurate, and quantitative point-of-care test to detect diabetic peripheral neuropathy.
NeuroMetrix, Inc. reported today that it had shipped its 100,000th Quell® wearable device for treatment of chronic pain since commercial launch in mid-2015. Quell device shipments have posted growth in each of the eight sequential quarters that it has been on the market.
Research Desk Line-up: NeuroMetrix Post Earnings Coverage LONDON, UK / ACCESSWIRE / July 26, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Teleflex ...
Categories: Yahoo FinanceGet free summary analysis NeuroMetrix, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of NeuroMetrix, Inc. – Medtronic plc (MDT-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 4.31 million, Net Earnings of USD -3.24 million. Gross margins ... Read more (Read more...)
NEW YORK, NY / ACCESSWIRE / July 20, 2017 / NeuroMetrix, Inc. (NASDAQ: NURO ) will be discussing their earnings results in their Q2 Earnings Call to be held on Thursday, July 20, 2017 at 8:00 AM Eastern ...
NeuroMetrix, Inc. announced today that it plans to issue its 2017 second quarter financial results before the opening of the market on Thursday July 20, 2017. The Company will host a conference call at 8:00 a.m., Eastern Time on July 20, 2017 to discuss its financial results as well as business developments affecting the Company.
NeuroMetrix, Inc. announced today that it has entered into a definitive securities purchase agreement with a healthcare dedicated institutional investor in connection with a private placement of 7,000 shares of Series F convertible preferred stock at a price of $1,000 per share.
NeuroMetrix, Inc. today reported that Michael MacDonald has been promoted to SVP and General Manager of Diagnostics. In this role, Mr. MacDonald will oversee the Company’s diagnostic products which include DPNCheck® and ADVANCE™.
NeuroMetrix, Inc. today provided an update on its data science initiative and the related Quell® Health Cloud.
NeuroMetrix, Inc. today provided an update on its Quell® clinical program. Quell is a wearable non-invasive neurostimulator that provides widespread analgesia for chronic pain.